Absolutely, Sukus. I think the big Pharmas will want to design and run future clinical trials though, of course, NWBO will have to agree with the trial design. I think DCVax + poly iclc will be the placebo for these trials.
Eventually, hopefully as soon as manufacturing growth allows, I think NWBO will apply for "tissue agnostic" designation which will allow it to be approved for use in most cancers. That may require confirmation trials which NWBO would run. And, of course, we'll run our own trials for DCVax-Direct, unless we get tissue agnostic approval for Direct, then the trials could be run by other BPs in collaboration with us.
Bullish
News 
Market Data 
Discover 
